Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03319745 · ClinicalTrials.gov registry record · Phase 2
Pembrolizumab in Treating Patients With Bladder Cancer Undergoing Radical Cystectomy
A Phase 2 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 23
- Enrollment target
NCT03319745: Completed Phase 2 study, sponsored by M.D. Anderson Cancer Center.
NCT03319745 is a Phase 2 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 23 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03319745, a Phase 2 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 23 participants
- Enrollment target
Study Summary
This phase II trial studies the side effects of pembrolizumab and to see how well it works in treating patients with bladder cancer who are undergoing surgery to remove the bladder. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
Interventions
- BIOLOGICAL Pembrolizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2018-01-11 |
| Est. Completion | 2023-05-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03319745
The ClinicalTrials.gov registry entry for NCT03319745 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Pembrolizumab is the first listed.
NCT03319745 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03319745 about?
NCT03319745 is a clinical study titled "Pembrolizumab in Treating Patients With Bladder Cancer Undergoing Radical Cystectomy". This phase II trial studies the side effects of pembrolizumab and to see how well it works in treating patients with bladder cancer who are undergoing surgery to remove the bladder. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, ...
What is the current status of trial NCT03319745?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 23 participants. The study started on 2018-01-11. Estimated completion is 2023-05-01.
What interventions are being tested in trial NCT03319745?
The interventions under investigation include: Pembrolizumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT03319745?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.